CO5611092A2 - Formulacion superfina de formoterol - Google Patents

Formulacion superfina de formoterol

Info

Publication number
CO5611092A2
CO5611092A2 CO04084191A CO04084191A CO5611092A2 CO 5611092 A2 CO5611092 A2 CO 5611092A2 CO 04084191 A CO04084191 A CO 04084191A CO 04084191 A CO04084191 A CO 04084191A CO 5611092 A2 CO5611092 A2 CO 5611092A2
Authority
CO
Colombia
Prior art keywords
less
wastewater
ppm
amount
pharmaceutical formulation
Prior art date
Application number
CO04084191A
Other languages
English (en)
Inventor
Rebecca Jaine Davies
Ganderton David
David Andrew Lewis
Brian John Meakin
Tanya Kathleen Church
Brambilla Gaetano
Ferraris Alessandra
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27790093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5611092(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP02004786A external-priority patent/EP1340492A1/en
Priority claimed from EP02023589A external-priority patent/EP1415647A1/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of CO5611092A2 publication Critical patent/CO5611092A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Abstract

1.- Una formulación de aerosol farmacéutico para ser administrada mediante inhaladores de dosis medidas presurizadas que comprende un ingrediente activo seleccionado de formoterol o un estereoisómero, sal y solvato fisiológicamente aceptables de los mismos, en una solución de un propelente HFA licuado, y un cosolvente, caracterizada porque la cantidad de agua residual es menor a 1500 ppm en el peso total de la formulación.2.- La formulación farmacéutica de conformidad con la reivindicación 1, caracterizada porque la cantidad de agua residual es menor a 1000 ppm.3.- La formulación farmacéutica de conformidad con la reivindicación 1, caracterizada porque la cantidad de agua residual es menor a 500 ppm.4.- La formulación farmacéutica de conformidad con las reivindicaciones 1-3, caracterizada porque la fracción de partículas igual o menor a 1.1 µm suministradas en el accionamiento del inhalador es superior o igual a 30% como se define mediante el contenido de las etapas S6-AF de un Impactor en Cascada Andersen, con relación al contenido de las etapas S6-AF, de acuerdo con el método al que se hace referencia en la descripción en la página 17 líneas 4 a 12.
CO04084191A 2002-03-01 2004-08-27 Formulacion superfina de formoterol CO5611092A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004786A EP1340492A1 (en) 2002-03-01 2002-03-01 Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP02023589A EP1415647A1 (en) 2002-10-23 2002-10-23 "Long-acting beta-2 agonists ultrafine formulations"

Publications (1)

Publication Number Publication Date
CO5611092A2 true CO5611092A2 (es) 2006-02-28

Family

ID=27790093

Family Applications (2)

Application Number Title Priority Date Filing Date
CO04084184A CO5611091A2 (es) 2002-03-01 2004-08-27 Inhaladores de dosis medidas presurizadas que contienen soluciones de beta-2 agonistas
CO04084191A CO5611092A2 (es) 2002-03-01 2004-08-27 Formulacion superfina de formoterol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CO04084184A CO5611091A2 (es) 2002-03-01 2004-08-27 Inhaladores de dosis medidas presurizadas que contienen soluciones de beta-2 agonistas

Country Status (36)

Country Link
US (4) US20050152846A1 (es)
EP (6) EP2201964B1 (es)
JP (3) JP2005523905A (es)
KR (2) KR100947409B1 (es)
CN (2) CN100398094C (es)
AR (2) AR038641A1 (es)
AT (1) ATE465712T1 (es)
AU (2) AU2003222753B2 (es)
BR (2) BRPI0308274B8 (es)
CA (2) CA2477881C (es)
CO (2) CO5611091A2 (es)
CY (4) CY1111133T1 (es)
DE (1) DE60332321D1 (es)
DK (4) DK3536344T3 (es)
EA (2) EA007735B1 (es)
ES (4) ES2779273T3 (es)
GE (2) GEP20063986B (es)
HK (1) HK1079425A1 (es)
HR (2) HRP20040753A2 (es)
HU (3) HUE048310T2 (es)
IL (3) IL163843A0 (es)
LT (3) LT3536344T (es)
MA (1) MA27175A1 (es)
ME (3) ME00077B (es)
MX (2) MXPA04008372A (es)
MY (2) MY137603A (es)
NO (2) NO20043625L (es)
NZ (2) NZ535018A (es)
PE (2) PE20030824A1 (es)
PL (2) PL209212B1 (es)
PT (4) PT1480615E (es)
RS (2) RS52387B (es)
SI (4) SI1480615T1 (es)
TN (2) TNSN04147A1 (es)
TW (2) TWI347197B (es)
WO (2) WO2003074024A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
WO2001089480A1 (en) * 2000-05-22 2001-11-29 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
AU2003222753B2 (en) * 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
EP1651224B1 (en) * 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
CN100457087C (zh) * 2004-02-27 2009-02-04 奇斯药制品公司 用于加压计量吸入器的稳定的药用溶液制剂
KR20070000476A (ko) * 2004-02-27 2007-01-02 키에시 파르마슈티시 엣스. 피. 에이. 압축화 계량된 도스흡입용 안정된 약제용액 제제
CN1950075A (zh) * 2004-05-13 2007-04-18 奇斯药制品公司 化学稳定性改善的医用气溶胶制剂产品
PL1809243T5 (pl) * 2004-07-02 2022-12-27 Boehringer Ingelheim International Gmbh Preparaty aerozolowe w postaci zawiesin z tg 227 ea jako propelent aerozolowy
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
CN101119706B (zh) * 2005-02-25 2013-04-17 奇斯药制品公司 用于加压计量吸入器的包含螯合剂的药物气雾制剂
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP1982709A1 (en) 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
GB2461752B (en) * 2008-07-14 2013-04-17 Neo Inhalation Products Ltd Metered dose inhaler
CA2741078A1 (en) * 2008-10-23 2010-04-29 Sunovion Pharmaceuticals Inc. Arformoterol and tiotropium compositions and methods for use
GB0918149D0 (en) 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
DK2515854T3 (da) 2009-12-23 2014-05-26 Chiesi Farma Spa Aerosolformulering for COPD
CN102665679B (zh) 2009-12-23 2014-11-26 奇斯药制品公司 用于copd的联合治疗
EP2360147A1 (en) * 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
CN105412122A (zh) * 2010-07-16 2016-03-23 希普拉有限公司 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
EP2919649B1 (en) * 2012-11-15 2021-12-22 JP Respiratory Technology AB Device and method for pulmonary function measurement
RU2504402C1 (ru) * 2012-11-20 2014-01-20 Шолекс Девелопмент Гмбх Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких
CN106667973A (zh) * 2017-01-22 2017-05-17 西咸新区世云工研坊生物科技有限公司 一种用于防雾霾损伤的组合物及其制备方法和喷剂
PE20221867A1 (es) 2020-01-28 2022-12-02 Chiesi Farm Spa Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada
WO2021165348A1 (en) 2020-02-20 2021-08-26 Chiesi Farmaceutici S.P.A. Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation
WO2023227783A1 (en) 2022-05-27 2023-11-30 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) * 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) * 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) * 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
IT1244441B (it) * 1990-09-13 1994-07-15 Chiesi Farma Spa Dispositivo per l'inalazione boccale di farmaci aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US6299863B1 (en) * 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
PL169046B1 (pl) * 1991-08-29 1996-05-31 Christoph Klein Przyrzad medyczny do inhalacji aerozolem PL PL PL PL PL
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
DK0673240T3 (da) * 1992-12-09 1999-10-11 Boehringer Ingelheim Pharma Stabiliserede medicinske aerosolopløsningsformuleringer
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) * 1992-12-11 1992-12-11 Astra Ab Efficient use
US5899201A (en) * 1993-05-26 1999-05-04 Minnesota Mining And Manufacturing Company Aerosol actuator
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining & Mfg Flunisolide aerosolformulierungen
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
EP1769819A3 (en) * 1995-04-14 2013-05-22 GlaxoSmithKline LLC Metered dose inhaler for fluticasone propionate
CA2217950C (en) * 1995-04-14 2001-12-25 Glaxo Wellcome Inc. Metered dose inhaler for albuterol
US5637505A (en) * 1995-05-19 1997-06-10 Chiron Diagnostics Corporation Method to prepare dye-based reference material
CA2264524A1 (en) * 1996-10-04 1998-04-09 Norihiro Shinkai Patch
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6413496B1 (en) * 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US6188933B1 (en) * 1997-05-12 2001-02-13 Light & Sound Design Ltd. Electronically controlled stage lighting system
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
NZ504021A (en) * 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6045784A (en) * 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
ATE283033T1 (de) 1998-07-24 2004-12-15 Jago Res Ag Medizinische aerosolformulierungen
CN1150890C (zh) * 1998-08-04 2004-05-26 杰格研究股份公司 药用气溶胶制剂
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
EP2266548B1 (de) * 1998-11-13 2020-05-20 Jagotec AG Trockenpulver zur inhalation
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) * 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
JP2003509359A (ja) * 1999-09-11 2003-03-11 グラクソ グループ リミテッド プロピオン酸フルチカゾンの医薬製剤
GB9928311D0 (en) * 1999-11-30 2000-01-26 Novartis Ag Organic compounds
US6578125B2 (en) 2000-02-14 2003-06-10 Sanyo Electric Co., Ltd. Memory access circuit and memory access control circuit
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
GB0009773D0 (en) 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
WO2001089480A1 (en) * 2000-05-22 2001-11-29 Chiesi Farmaceutici S.P.A. Stable pharmaceutical solution formulations for pressurised metered dose inhalers
EP1241113A1 (en) 2001-03-12 2002-09-18 CHIESI FARMACEUTICI S.p.A. Inhaler with means for improving chemical stability of medicinal aerosol solution contained therein
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
AU2003222753B2 (en) * 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
EP1595531A1 (en) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers

Also Published As

Publication number Publication date
MXPA04008369A (es) 2004-11-26
PT1480615E (pt) 2010-06-16
IL163843A0 (en) 2005-12-18
EP1480615A1 (en) 2004-12-01
CY1122027T1 (el) 2020-10-14
HRP20040752A2 (en) 2004-12-31
AU2003210370C1 (en) 2008-03-13
NO20043626L (no) 2004-08-31
PE20030824A1 (es) 2003-11-07
EA200401007A1 (ru) 2005-04-28
HUE044926T2 (hu) 2019-11-28
AU2003222753A1 (en) 2003-09-16
WO2003074025A2 (en) 2003-09-12
RS76704A (en) 2007-02-05
CN100398094C (zh) 2008-07-02
TWI347197B (en) 2011-08-21
EP1480617A2 (en) 2004-12-01
EA200401005A1 (ru) 2005-08-25
EP2201964A3 (en) 2013-01-23
LT3494995T (lt) 2020-04-10
AU2003210370B2 (en) 2007-08-30
TW200303752A (en) 2003-09-16
PT3494995T (pt) 2020-03-30
CN1638730A (zh) 2005-07-13
AR038644A1 (es) 2005-01-19
SI3384931T1 (sl) 2019-11-29
IL163843A (en) 2011-08-31
NZ535017A (en) 2007-02-23
HUE048310T2 (hu) 2020-07-28
KR100947409B1 (ko) 2010-03-12
MEP30208A (en) 2010-10-10
BRPI0308274B1 (pt) 2018-10-30
PE20030827A1 (es) 2003-11-06
NO20043625L (no) 2004-09-29
SI3494995T1 (sl) 2020-08-31
HK1079425A1 (en) 2006-04-07
EP2201964B1 (en) 2018-08-08
BR0308274A (pt) 2004-12-28
PL372173A1 (en) 2005-07-11
DE60332321D1 (de) 2010-06-10
MXPA04008372A (es) 2004-11-26
DK3494995T3 (da) 2020-03-23
BR0308275A (pt) 2004-12-28
EP3536344B1 (en) 2020-02-19
CN1638729A (zh) 2005-07-13
US8313732B2 (en) 2012-11-20
GEP20063986B (en) 2006-12-11
RS52387B (en) 2013-02-28
ME00077B (me) 2010-06-10
ES2779273T3 (es) 2020-08-14
JP2005524664A (ja) 2005-08-18
HRP20040753A2 (en) 2004-12-31
NZ535018A (en) 2007-02-23
PT3536344T (pt) 2020-03-26
US20110061651A1 (en) 2011-03-17
US20050152846A1 (en) 2005-07-14
EA007735B1 (ru) 2006-12-29
DK3384931T3 (da) 2019-09-16
AU2003210370A1 (en) 2003-09-16
PL209212B1 (pl) 2011-08-31
EP3494995A2 (en) 2019-06-12
DK1480615T3 (da) 2010-07-12
CA2477881A1 (en) 2003-09-12
ES2780127T3 (es) 2020-08-24
TW200303767A (en) 2003-09-16
IL163844A0 (en) 2005-12-18
MY137603A (en) 2009-02-27
PL372292A1 (en) 2005-07-11
MY143517A (en) 2011-05-31
HUE049426T2 (hu) 2020-09-28
EP3536344A1 (en) 2019-09-11
AU2003222753B2 (en) 2008-04-17
EP3494995B1 (en) 2020-02-19
CA2477881C (en) 2011-02-01
EP2201964A2 (en) 2010-06-30
US20090263488A1 (en) 2009-10-22
TNSN04149A1 (en) 2007-03-12
MA27175A1 (fr) 2005-01-03
RS76604A (en) 2006-10-27
DK3536344T3 (da) 2020-03-16
CA2477885A1 (en) 2003-09-12
EP3494995A3 (en) 2019-07-24
US20050154013A1 (en) 2005-07-14
SI3536344T1 (sl) 2020-06-30
EP3384931B1 (en) 2019-07-24
ATE465712T1 (de) 2010-05-15
EP3384931A1 (en) 2018-10-10
HRP20040752B1 (hr) 2012-10-31
WO2003074024A1 (en) 2003-09-12
GEP20063876B (en) 2006-07-10
BRPI0308274B8 (pt) 2021-05-25
SI1480615T1 (sl) 2010-07-30
ES2745064T3 (es) 2020-02-27
KR100961603B1 (ko) 2010-06-04
CY1122851T1 (el) 2021-05-05
JP2010215637A (ja) 2010-09-30
EA008592B1 (ru) 2007-06-29
LT3536344T (lt) 2020-04-10
LT3384931T (lt) 2019-09-25
WO2003074025A3 (en) 2003-12-24
CY1111133T1 (el) 2015-06-11
MEP30108A (en) 2010-06-10
KR20040093079A (ko) 2004-11-04
ES2342463T3 (es) 2010-07-07
KR20040093080A (ko) 2004-11-04
JP2005523905A (ja) 2005-08-11
PT3384931T (pt) 2019-09-26
CA2477885C (en) 2010-12-21
CO5611091A2 (es) 2006-02-28
TNSN04147A1 (en) 2007-03-12
CY1122875T1 (el) 2021-05-05
EP1480615B1 (en) 2010-04-28
NO342575B1 (no) 2018-06-18
AR038641A1 (es) 2005-01-19

Similar Documents

Publication Publication Date Title
CO5611092A2 (es) Formulacion superfina de formoterol
AR101593A2 (es) Formulación superfina de formoterol
ATE308317T1 (de) Zubereitungen mit einem anticholinergischen wirkstoff für die behandlung der chronischen obstruktiven lungenerkrankung
MX9300620A (es) Formulacion farmaceutica en aerosol e inhalador para la administracion de dipropionato de beclometasona.
CO5031245A1 (es) Inhaladores de dosis regulada a presion y formulaciones farmaceuticas de aerosol
MX9207200A (es) Formulacion farmaceutica en aerosol, bote para suministrar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
AR018410A1 (es) Uso de una composicion para la manufactura de un medicamento que se usa para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitentey/o episodios de asma cronico y metodo para la prevencion o tratamiento de un estado agudo de asma y/o asma intermitente y/o episodios de asma cron
NZ534040A (en) Metered dose inhaler
CO4940408A1 (es) Composicion de aerosol farmaceutico
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
MX9207205A (es) Formulacion farmaceutica en aerosol, bote para suministrarar dicha formulacion e inhalador de dosis dosificada que comprende dicho bote.
AR022090A1 (es) PARTíCULAS PARA LA ADMINISTRACIoN DE UN AGENTE ACTIVO A LOS ALVÉOLOS DE UN PACIENTE HUMANO, UN MÉTODO PARA SU PREPARACIoN, Y EL USO DE LAS MISMAS PARA LA PREPARACIoN DE UN MEDICAMENTO PARA INHALACIoN
CL2022002235A1 (es) Inhaladores dosificadores presurizados que comprenden una formulación farmacéutica amortiguada
AR009370A1 (es) UNA COMPOSICION FARMACEUTICA EN AEROSOL ADECUADA PARA LA ADMINISTRACION DE BUDESONIDA, UN PRODUCTO FARMACEUTICO QUE LA CONTIENE, UN METODO PARAADMINISTRAR BUDESONIDA Y USO DE UNA MEZCLA DE HFA 134a Y HFA 227
BR0208012A (pt) Usos de pelo menos duas drogas e um propelente hfa e de pelo menos uma composição farmaceêutica, e, inalador acondicionado para tratar asma
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol
CL2023000998A1 (es) Formulación farmacéutica para inhalador presurizado de dosis medidas
AR040450A1 (es) Formulacion superfina de salmeterol
PE20011271A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
BR0309114A (pt) Uso de carboidratos derivados particulados em composições farmacêuticas em pó seco, composição farmacêutica em pó seco para terapia de inalação, método de tratamento ou profilaxia de distúrbios respiratórios, uso de uma composição farmacêutica em pó seco, dispositivo de inalação, e, embalagem de medicamento
AR078494A1 (es) Formulaciones farmaceuticas en aerosol de formoterol y dipropionato de beclometasona
CL2012000947A1 (es) Formulación en suspensión para inhalar de dosis medida que comprende fumarato de formoterol dihidratado y propionato de fluticasona y microlin sodico en un propelente hfa; composicion farmaceutica; un producto; uso de 0,01 a 0,1% cromolin sodico, util en asma y rinitis.
SG159550A1 (en) Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
CO2022012207A2 (es) Inhaladores de dosis medida presurizada que comprenden una formulación farmacéutica amortiguada

Legal Events

Date Code Title Description
FC Application refused